| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
AJP - Regulatory, Integrative and Comparative Physiology, Vol 271, Issue 4 1090-R1095, Copyright © 1996 by American Physiological Society
ARTICLES |
H. M. Siragy, A. A. Jaffa, H. S. Margolius and R. M. Carey
Department of Medicine, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
Previous studies have shown that sodium depletion is associated with an increase in renal kallikrein-kinin system activity. This system may play an important role in counterbalancing the renal effects of the renin-angiotensin system. In this study, we examined whether the renal renin-angiotensin system participates in the regulation of renal bradykinin (BK) levels during sodium depletion. We measured changes in renal excretory and hemodynamic function, renal interstitial fluid (RIF) BK, and RIF and urinary guanosine 3',5'-cyclic monophosphate (cGMP) and prostaglandin E2 (PGE2) in conscious uninephrectomized dogs (n = 5) in sodium metabolic balance (10 meq/day) in response to intrarenal arterial administration of the renin inhibitor ACRIP (0.2 microgram.kg-1.min-1) or angiotensin II AT1-receptor blocker losartan (100 ng.kg-1.min-1). ACRIP and losartan increased urine flow rate from 0.75 +/- 0.06 to 1.6 +/- 0.03 and 1.5 +/- 0.05 ml/min, respectively (each P < 0.001), and urine sodium excretion from 5.4 +/- 0.7 to 18.3 +/- 1.3 and 15.9 +/- 1.2 meq/min, respectively (each P < 0.001). Glomerular filtration rate and renal plasma flow increased only during losartan administration (P < 0.05). ACRIP decreased RIF BK by 48%, from 33.1 +/- 3.8 to 17.4 +/- 4.1 pg/min (P < 0.01). ACRIP decreased RIF cGMP by 38%, from 0.69 +/- 0.08 to 0.43 +/- 0.1 pmol/min (P < 0.01); urinary cGMP by 16%, from 0.63 +/- 0.05 to 0.53 +/- 0.02 pmol/min (P < 0.05); and RIF PGE2 by 46%, from 10.5 +/- 1.1 to 5.7 +/- 1.1 pg/min (P < 0.01). Urinary PGE2 was unchanged by ACRIP. Losartan decreased RIF PGE2 by 71%, from 10.8 +/- 0.6 to 3.1 +/- 0.6 pg/min (P < 0.01) but failed to change RIF BK, RIF cGMP, urinary cGMP, or urinary PGE2. These data suggest that the renin-angiotensin system tonically stimulates renal BK production and cGMP formation via a non-AT1 angiotensin receptor and renal PGE2 production via the AT1 receptor.
This article has been cited by other articles:
|
|
 |
|
  Y. Tan, J.-S. Keum, B. Wang, M. B. McHenry, S. R. Lipsitz, and A. A. Jaffa Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1026 - F1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Salomone, N. L. Howell, H. E. McGrath, B. A. Kemp, S. R. Keller, J. J. Gildea, R. A. Felder, and R. M. Carey Intrarenal Dopamine D1-Like Receptor Stimulation Induces Natriuresis via an Angiotensin Type-2 Receptor Mechanism Hypertension, January 1, 2007; 49(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Carey Cardiovascular and Renal Regulation by the Angiotensin Type 2 Receptor: The AT2 Receptor Comes of Age Hypertension, May 1, 2005; 45(5): 840 - 844. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tan, F. N. Hutchison, and A. A. Jaffa Mechanisms of angiotensin II-induced expression of B2 kinin receptors Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H926 - H932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Schmaier The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yuan, M. Liang, Z. Yang, E. Rute, N. Taylor, M. Olivier, and A. W. Cowley Jr. Gene expression reveals vulnerability to oxidative stress and interstitial fibrosis of renal outer medulla to nonhypertensive elevations of ANG II Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2003; 284(5): R1219 - R1230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rhinehart, C. A. Handelsman, E. P. Silldorff, and T. L. Pallone ANG II AT2 receptor modulates AT1 receptor-mediated descending vasa recta endothelial Ca2+ signaling Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H779 - H789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Slim, F. Torremocha, T. Moreau, A. Pizard, S. C. Hunt, A. Vuagnat, G. H. Williams, F. Gauthier, X. Jeunemaitre, and F. Alhenc-Gelas Loss-of-Function Polymorphism of the Human Kallikrein Gene with Reduced Urinary Kallikrein Activity J. Am. Soc. Nephrol., April 1, 2002; 13(4): 968 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Berry, R. Touyz, A. F. Dominiczak, R. C. Webb, and D. G. Johns Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2337 - H2365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Souza dos Santos, K. T. Passaglio, J. B. Pesquero, M. Bader, and A. C. Simoes e Silva Interactions Between Angiotensin-(1-7), Kinins, and Angiotensin II in Kidney and Blood Vessels Hypertension, September 1, 2001; 38(3): 660 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Siragy, M. de Gasparo, M. El-Kersh, and R. M. Carey Angiotensin-Converting Enzyme Inhibition Potentiates Angiotensin II Type 1 Receptor Effects on Renal Bradykinin and cGMP Hypertension, August 1, 2001; 38(2): 183 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Moore, N. T. Heiderstadt, E. Huang, N. L. Howell, Z.-Q. Wang, H. M. Siragy, and R. M. Carey Selective Inhibition of the Renal Angiotensin Type 2 Receptor Increases Blood Pressure in Conscious Rats Hypertension, May 1, 2001; 37(5): 1285 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Pallone, E. P. Silldorff, and Z. Zhang Inhibition of calcium signaling in descending vasa recta endothelia by ANG II Am J Physiol Heart Circ Physiol, April 1, 2000; 278(4): H1248 - H1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Carey, Z.-Q. Wang, and H. M. Siragy Role of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure and Renal Function Hypertension, January 1, 2000; 35(1): 155 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tschope, A. Reinecke, U. Seidl, M. Yu, V. Gavriluk, U. Riester, P. Gohlke, K. Graf, M. Bader, U. Hilgenfeldt, et al. Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2333 - H2340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Siragy, T. Inagami, T. Ichiki, and R. M. Carey Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor PNAS, May 25, 1999; 96(11): 6506 - 6510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Campbell, A. Kladis, T. A. Briscoe, and J. Zhuo Type 2 Bradykinin-Receptor Antagonism Does Not Modify Kinin or Angiotensin Peptide Levels Hypertension, May 1, 1999; 33(5): 1233 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Azizi, R. Agarwal, H. Gallois, O. Piot, J. V. Gainer, and N. J. Brown Bradykinin and Inhibition of Angiotensin-Converting Enzyme in Hypertension N. Engl. J. Med., March 25, 1999; 340(12): 967 - 969. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
